Bicara Therapeutics Inc.
BCAX
$26.87
$0.532.01%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.74M | 8.13M | 7.70M | 7.22M | 7.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.24M | 41.12M | 40.68M | 32.02M | 41.79M |
| Operating Income | -60.24M | -41.12M | -40.68M | -32.02M | -41.79M |
| Income Before Tax | -56.16M | -37.33M | -36.29M | -27.34M | -36.77M |
| Income Tax Expenses | 52.00K | 53.00K | 40.00K | 52.00K | 72.00K |
| Earnings from Continuing Operations | -56.21M | -37.39M | -36.33M | -27.39M | -36.85M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.21M | -37.39M | -36.33M | -27.39M | -36.85M |
| EBIT | -60.24M | -41.12M | -40.68M | -32.02M | -41.79M |
| EBITDA | -60.20M | -41.08M | -40.65M | -32.00M | -41.77M |
| EPS Basic | -0.93 | -0.68 | -0.67 | -0.50 | -0.68 |
| Normalized Basic EPS | -0.58 | -0.42 | -0.42 | -0.31 | -0.42 |
| EPS Diluted | -0.93 | -0.68 | -0.67 | -0.50 | -0.68 |
| Normalized Diluted EPS | -0.58 | -0.42 | -0.42 | -0.31 | -0.42 |
| Average Basic Shares Outstanding | 60.72M | 55.14M | 54.56M | 54.54M | 54.46M |
| Average Diluted Shares Outstanding | 60.72M | 55.14M | 54.56M | 54.54M | 54.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |